C Bio Investors

C Bio Investors

C Bio Investors was formed following the 2017 sale of CoverMyMeds, the electronic prior-authorization platform co-founded by Matt Scantland and Sam Rajan, to McKesson Corporation for $1.4 billion. The firm manages the proceeds of that transaction and functions as the single-family office for the founding principals, with a footprint spanning Columbus, Dublin, and Philadelphia. The office deploys capital primarily into early-stage and growth healthcare technology, digital health, and AI-driven life-sciences ventures. Its mandate spans direct equity investments, co-investments alongside venture funds, and selective fund commitments. Portfolio exposures, while privately held, are concentrated in the operational layer between payers, providers, and pharmaceutical fulfillment — a direct extension of the founding team's domain expertise. The geographic focus is North America, with a concentration in the Midwest and Mid-Atlantic health-tech corridors. The firm operates with a lean structure, typical of post-exit single-family offices where the principals remain actively engaged in sourcing and underwriting. The office maintains a low public profile, does not publish a website, and has not disclosed aggregate assets under management or total deployment to date. In 2023 the firm participated in seed-stage rounds for several AI-enabled clinical-workflow startups, according to regulatory filings. The family office's structural differentiator is its embeddedness in the healthcare-IT operator network that scaled CoverMyMeds: the principals' relationships with health-system executives, EHR vendors, and pharmacy benefit managers create a specialized deal-origination channel unavailable to generalist venture firms. There is no publicly disclosed philanthropic foundation or adjacent investment vehicle, suggesting the office operates as a unified balance-sheet investor.